![]() |
Name |
Aspergillazine A
|
Molecular Formula | C20H20N2O8S | |
IUPAC Name* |
(1S,4S,5R,8R,9R)-N-(7,8-dimethoxy-2-oxochromen-3-yl)-5,9-dihydroxy-3-oxa-11-thia-2-azatricyclo[6.2.1.04,9]undec-6-ene-1-carboxamide
|
|
SMILES |
COC1=C(C2=C(C=C1)C=C(C(=O)O2)NC(=O)[C@]34C[C@@]5([C@H](S3)C=C[C@H]([C@@H]5ON4)O)O)OC
|
|
InChI |
InChI=1S/C20H20N2O8S/c1-27-12-5-3-9-7-10(17(24)29-14(9)15(12)28-2)21-18(25)20-8-19(26)13(31-20)6-4-11(23)16(19)30-22-20/h3-7,11,13,16,22-23,26H,8H2,1-2H3,(H,21,25)/t11-,13-,16+,19+,20+/m1/s1
|
|
InChIKey |
BORNJBKYDWJXSF-JKRAONCPSA-N
|
|
Synonyms |
Aspergillazine A; CHEMBL4077444; SCHEMBL20203937; (1S,4S,5R,8R,9R)-N-(7,8-dimethoxy-2-oxochromen-3-yl)-5,9-dihydroxy-3-oxa-11-thia-2-azatricyclo[6.2.1.04,9]undec-6-ene-1-carboxamide
|
|
CAS | NA | |
PubChem CID | 15975698 | |
ChEMBL ID | CHEMBL4077444 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 448.4 | ALogp: | 0.3 |
HBD: | 4 | HBA: | 10 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 161.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 31 | QED Weighted: | 0.394 |
Caco-2 Permeability: | -5.85 | MDCK Permeability: | 0.00000618 |
Pgp-inhibitor: | 0.028 | Pgp-substrate: | 0.935 |
Human Intestinal Absorption (HIA): | 0.761 | 20% Bioavailability (F20%): | 0.882 |
30% Bioavailability (F30%): | 0.977 |
Blood-Brain-Barrier Penetration (BBB): | 0.257 | Plasma Protein Binding (PPB): | 74.46% |
Volume Distribution (VD): | 1.433 | Fu: | 18.31% |
CYP1A2-inhibitor: | 0.319 | CYP1A2-substrate: | 0.979 |
CYP2C19-inhibitor: | 0.053 | CYP2C19-substrate: | 0.342 |
CYP2C9-inhibitor: | 0.055 | CYP2C9-substrate: | 0.603 |
CYP2D6-inhibitor: | 0.019 | CYP2D6-substrate: | 0.305 |
CYP3A4-inhibitor: | 0.565 | CYP3A4-substrate: | 0.648 |
Clearance (CL): | 3.407 | Half-life (T1/2): | 0.545 |
hERG Blockers: | 0.041 | Human Hepatotoxicity (H-HT): | 0.833 |
Drug-inuced Liver Injury (DILI): | 0.982 | AMES Toxicity: | 0.613 |
Rat Oral Acute Toxicity: | 0.365 | Maximum Recommended Daily Dose: | 0.862 |
Skin Sensitization: | 0.278 | Carcinogencity: | 0.395 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.904 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002091 | ![]() |
0.617 | D08SKH | ![]() |
0.291 | ||
ENC004309 | ![]() |
0.559 | D03DIG | ![]() |
0.271 | ||
ENC002524 | ![]() |
0.522 | D06GCK | ![]() |
0.268 | ||
ENC004276 | ![]() |
0.466 | D0E6OC | ![]() |
0.262 | ||
ENC004279 | ![]() |
0.421 | D0W8WB | ![]() |
0.260 | ||
ENC004278 | ![]() |
0.421 | D06TQZ | ![]() |
0.256 | ||
ENC004277 | ![]() |
0.406 | D0L1JW | ![]() |
0.256 | ||
ENC003659 | ![]() |
0.391 | D09DHY | ![]() |
0.256 | ||
ENC003545 | ![]() |
0.382 | D0Q0PR | ![]() |
0.248 | ||
ENC003544 | ![]() |
0.382 | D0G4KG | ![]() |
0.239 |